Asthma & COPD Drug Ref
iOS app by ATIF ELNIL. Medical · ATIF ELNIL
- Store rating
- 0 / 5
- Store rating count
- 0
- Download price
- 9.99 USD
- In-app purchases
- Unknown
- Version
- 1.0.1
- Listing last refreshed
- 2026-09-10
View the original store listing
Store description excerpt
IMPORTANT: This app is intended for use by qualified healthcare professionals only. Always seek the advice of a qualified clinician before making any medical or prescribing decisions. Asthma & COPD Drug Ref is a comprehensive evidence-based respiratory pharmacology reference for doctors, nurses, pharmacists and respiratory specialist nurses. Built for the clinic, ward and emergency department. DRUG CLASSES REFERENCE Complete inhaled and oral drug reference across 6 classes: - SABA: salbutamol, terbutaline — doses, acute and routine use - LABA: salmeterol, formoterol, indacaterol, vilanterol, olodaterol - LAMA: tiotropium, umeclidinium, glycopyrronium, aclidinium, ipratropium - ICS: beclometasone, budesonide, fluticasone propionate and furoate, ciclesonide - Combination inhalers: ICS/LABA, LABA/LAMA, and triple therapy (ICS/LABA/LAMA) - Other agents: montelukast, theophylline, roflumilast, cromones STEP THERAPY - GINA 2024: 5-step asthma treatment ladder with as-needed ICS/formoterol guidance - GOLD 2024: ABCE group framework and pharmacological escalation strategy - Step-up and step-down criteria with review intervals BIOLOGIC THERAPY 7 approved biologics with eligibility criteria, NICE TA references and dosing: - Omalizumab (NICE TA278) — anti-IgE, allergic asthma - Mepolizumab (NICE TA431) — anti-IL-5, eosinophilic asthma - Benralizumab (NICE TA565) — anti-IL-5 receptor - Dupilumab (NICE TA751) — anti-IL-4/IL-13, broadest T2 indication - Tezepelumab (NICE TA878) — anti-TSLP, effective in T2-low asthma - Reslizumab — IV anti-IL-5 - Dupilumab for COPD (2024) — BOREAS/NOTUS trials ACUTE MANAGEMENT - Acute severe asthma: severity classification (moderate/severe/life-threatening/near-fatal) - 7-step treatment protocol including IV magnesium, IV salbutamol, ICU referral criteria - COPD exacerbation: controlled oxygen, NIV (BIPAP) criteria and settings - Antibiotic guidance — evidence-based indications INHALER GUIDE - pMDI, DPI, soft mist inhaler (Respimat) and nebuliser technique - Spacer devices — indications, cleaning, replacement - Device selection guide including environmental considerations (NICE NG80) OXYGEN THERAPY - SpO2 targets by condition — including COPD controlled oxygen 88–92% - Delivery devices: nasal cannula, Venturi mask, non-rebreather, HFNO, NIV - Long-term oxygen therapy (LTOT) criteria — NICE NG115 GINA & GOLD 2024 GUIDELINES - Asthma diagnosis, control assessment (ACQ/ACT), key GINA 2024 recommendations - GOLD ABCD groups, spirometric grading, non-pharmacological management - Asthma vs COPD comparison table SPECIAL SITUATIONS - Pregnancy: safe and unsafe drugs, acute asthma management in pregnancy - Elderly: device considerations, polypharmacy interactions, spirometry - Occupational asthma: causes, diagnosis, RIDDOR reporting - Difficult/severe asthma: distinguishing difficult-to-treat from true severe asthma SOURCES AND REFERENCES Full tappable reference list: GINA 2024, GOLD 2024, BTS/SIGN 2019, NICE NG115, NICE TA27
Review coverage
AppRill has captured 0 reviews for this app. This is a collected sample, separate from the store rating count. Latest review capture: Not captured yet.
Recent captured chart positions
No chart positions have been captured for this app yet.
Chart position, rating count and review coverage do not establish downloads, revenue or profit. Understand the differences.